Qiming Venture Partners
Undisclosed; no standardized check range was found. · seed, series-a, series-b, growth · China, with US and selective global reach
China-focused technology, consumer and healthcare investor with $9.5B raised, 580+ companies, 210+ exits, 80+ unicorns and a $2.5B Fund VIII closed in 2022; roughly 70% of investments are Series A.
Tier 2 · ranked #73china
Visit / pitchOfficial siteOpen in the live directory
Key facts
| Fund size | $2.5B Fund VIII (2022); $9.5B platform capital raised |
| Stage | seed, series-a, series-b, growth |
| Typical first check | Undisclosed; no standardized check range was found. |
| Sectors | healthcare, consumer, enterprise, ai, deep-tech |
| Geography | China, with US and selective global reach |
| Status | open |
Always confirm on the official page before applying — dates and terms change.
Background
Qiming publishes strong scale, selectivity and stage evidence: 11 USD and seven RMB funds, outcome counts, one company funded per 30 reviewed and a Series A concentration. The 2022 closed vehicle is used instead of treating a later fundraising target as deployed capital.
How the application really works
No dedicated founder pitch route was confirmed. Target a current technology/consumer or healthcare partner through a trusted introduction.
Tips
- Make a strong Series A case; the firm says about 70% of investments occur there.
- Route explicitly to technology/consumer or healthcare.
Watch out for
- Treating a fundraising target as a closed fund.
- Assuming a standard check or ownership target not published by the firm.
Track record
- More than 210 exits and more than 80 unicorns reported by the firm.
- The firm reports backing more than 580 companies.
The firm says it funds about one of every 30 companies reviewed.
Investment thesis
Back category-defining technology/consumer and healthcare companies in China, primarily from Series A, and support them through scale and exit.
How to reach them
- Target a current sector partner through a trusted introduction.
Notable portfolio
580+ companies; see official portfolio and newsroom
Frequently asked questions
- What stage does the firm invest at?
- Early through growth, with approximately 70% of investments at Series A.
- What is the latest disclosed fund or capital base?
- $2.5B Fund VIII (main plus healthcare) closed in 2022; $9.5B raised across the platform.
- What check size does it write?
- Undisclosed; no standardized check range was found.
- Where does it invest?
- China, with US and selective global reach
- How can a founder approach the firm?
- No dedicated founder pitch route was confirmed. Target a current technology/consumer or healthcare partner through a trusted introduction.
- What remains undisclosed?
- Check range, uniform lead/ownership policy, reserves, decision timing and public founder intake remain undisclosed.
Related venture funds
Sources
- www.qimingvc.com/en — Current activity and platform overview. (checked 2026-08-10)
- www.qimingvc.com/en/about — Fund count, capital raised, company/outcome counts, selectivity and Series A concentration. (checked 2026-08-10)
- www.qimingvc.com/en/team — Current investment leadership. (checked 2026-08-10)
- www.qimingvc.com/en/node/5608 — Official $3.2B 2022 fundraising announcement, including $2.5B Fund VIII. (checked 2026-08-10)
- www.qimingvc.com/en/newsroom — Current deployment activity. (checked 2026-08-10)